Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab-800CW Fluorescence Imaging in IBD and RA
NCT03938701Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2024
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab-800CW in inflammatory bowel disease (IBD), rheumatoid arthritis (RA), sponsored by University Medical Center Groningen. Started Aug 2024; status: recruiting.
02
Drugs
adalimumab-800CW
03
Conditions
inflammatory bowel disease (IBD)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03938701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938701.